4Q EARNINGS: Lilly hit by Cymbalta patent loss, looks ahead
This article was originally published in Scrip
Executive Summary
Eli Lilly felt the loss of patent protection for its biggest drug Cymbalta in the fourth quarter and pushed forward with plans to introduce new medicines this year in hopes of getting back on track in 2015.